Navigation Links
China-Biotics, Inc. to Attend Digestive Disease Week 2009
Date:5/26/2009

SHANGHAI, May 26 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics", "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced that management will attend Digestive Disease Week 2009 ("DDW 2009").

Digestive Disease Week (DDW) is the largest and most prestigious meeting in the world for gastrointestinal professionals in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Every year, it attracts approximately 16,000 physicians, researchers and academics from around the world. The schedule for DDW 2009 is:

     May 30 - June 4, 2009
     Exhibit Dates: May 31 - June 3, 2009
     McCormick Place
     Chicago, IL

"We are excited to attend this important industry event, which we believe will enhance our profile with scientists and medical professionals in North America," said Mr. Jinan Song, Chairman and Chief Executive Officer of China-Biotics. "We look forward to leveraging this tremendous platform to enhance our visibility in the international community."

About China-Biotics, Inc.

China-Biotics, Inc. ("China-Biotics," "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company has operations in Shanghai. Its proprietary product portfolio contains live microbial nutritional supplements under the "Shining" brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang. China-Biotics plans to launch 300 Shining brand retail outlets in major cities in China. Currently, China-Biotics is strategically expanding its production capacity of probiotics to meet growing demand in the bulk additive market. For more information, please visit http://www.chn-biotics.com .

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the Company's ability to market existing and new products, ability to access to capital for expansion, and changes from anticipated levels of sales, future national or regional economic and competitive conditions, market acceptance of its retail store concept, changes in relationships with customers, dependence on its flagship product profits and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    For more information, please contact:

    CCG Investor Relations
     Crocker Coulson, President
     Phone: +1-646-213-1915 (New York)
     Email: crocker.coulson@ccgir.com
     Web:  http://www.ccgirasia.com

'/>"/>
SOURCE China-Biotics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. to Present at CCG Investor Relations China Rising Conference
2. China-Biotics, Inc. Supplies Probiotics as Additive for Poultry Feed
3. China-Biotics, Inc. Appoints New Chief Financial Officer
4. China-Biotics, Inc. to Present at Roth Capital Partners 21st Annual OC Growth Stock Conference
5. China-Biotics, Inc. Receives Manufacturing Certificate for New Products
6. China-Biotics, Inc. Reports Second Quarter 2009 Financial Results
7. China-Biotics, Inc. Retains KPMG for the Implementation of Sarbanes-Oxley Act Section 404
8. China-Biotics, Inc. Approved to List on the Nasdaq Global Market
9. China-Biotics, Inc. Announces Results of 2008 Annual General Meeting of Shareholders
10. China-Biotics, Inc. Provides Update on Construction of New Manufacturing Facility
11. China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: ... in China , today announced that ... on February 4, 2016 a preliminary non-binding proposal letter, ... PKU V-Ming ( Shanghai ) Investment Holdings ... ( Shenzhen ) Fund Management Co., Ltd., ...
(Date:2/3/2016)...   ViaCyte, Inc ., a leading, privately-held ... cell-derived islet replacement therapy for the treatment of ... that ViaCyte and Janssen Biotech, Inc., one of ... have agreed to consolidate the assets of the ... ViaCyte with an exclusive license to all BetaLogics ...
(Date:2/3/2016)... NEW YORK and HOLLISTON, Mass., Feb. 3, ... (Nasdaq: HART ), a biotechnology company developing ... esophagus, trachea and bronchus, today announced that CEO ... BIO CEO & Investor Conference on ... in New York City . ...
(Date:2/3/2016)... ... February 03, 2016 , ... ... Unix visualization solutions today announced the addition of a powerful “Session Preview” feature ... see the current state of the remote Linux desktop or other applications (sessions) ...
Breaking Biology Technology:
(Date:2/2/2016)... --Technology Enhancements Accelerate Growth of X-ray Imaging This ... computed radiography markets in Thailand , ... (TIM). It provides an in-depth analysis of ... regional market drivers and restraints. The study offers revenue ... attractiveness, both for digital and computed radiography. Market participants ...
(Date:2/1/2016)... BURNABY, Canada , February 1, 2016 ... new technological advancements to drive global touchfree intuitive gesture ...   --> Rising sales of consumer electronics ... intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ...
(Date:1/28/2016)... -- Synaptics (NASDAQ: SYNA ), a leading developer of human ... December 31, 2015. --> --> ... 2 percent compared to the comparable quarter last year to $470.5 ... $35.0 million, or $0.93 per diluted share. ... quarter of fiscal 2016 grew 9 percent over the prior year ...
Breaking Biology News(10 mins):